The role of VWF in the immunogenicity of FVIII

Thrombosis Research

Volumn 122, Issue SUPPL. 2, 2008, Pages

  Lacroix Desmazes, Sébastien ^a   Repessé, Yohann ^a   Kaveri, Srinivas V ^a   Dasgupta, Suryasarathi ^a  

^a INSERM   (France)

Author keywords

Antigen presenting cells; FVIII immunogenicity; Inhibitory antibodies; T cell activation; von Willebrand factor (VWF)

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ANTIGEN PRESENTING CELL; ARTICLE; CELL MATURATION; DENDRITIC CELL; DOSE RESPONSE; HEMOPHILIA A; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGEN PRESENTATION; FACTOR VIII; HEMOPHILIA A; HUMANS; VON WILLEBRAND FACTOR;

EID: 44849100303     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(08)70002-1     Document Type: Article

References (11)

1. Kreuz W., Joseph-Steiner J., Mentzer D., Auerswald G., Beeg T., and Becker S. Successful immunotolerance therapy of F VIII-inhibitor in children after changing from high to intermediate purity F VIII concentrate. Ann Hematol 72 Suppl 1 (1996) pA85 abstract 339.
2. Franchini M., and Lippi G. The role of von Willebrand factor in hemorrhagic and thrombotic disorders. Crit Rev Clin Lab Sci 44 (2007) 115-149
3. Sadler J. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 67 (1998) 395-424
4. Gensana M., Altisent C., Aznar J., Casaña P., Hernández F., Jorquera J., et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 7 (2001) 369-374
5. Kallas A., and Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 7 (2001) 375-380
6. Goudemand J., Rothschild C., Demiguel V., Vinciguerrat C., Lambert T., Chambost H., et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107 (2006) 46-51
7. Gouw S., van der Bom J., Auerswald G., Ettinghausen C., Tedgård U., and van den Berg H. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 109 (2007) 4693-4697
8. Behrmann M., Pasi J., Saint-Remy J., Kotitschke R., and Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 88 (2002) 221-229
9. Delignat S., Dasgupta S., André S., Navarret A.-M., Kaveri S., Bayry J., et al. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica 92 (2007) 1423-1426
10. Dasgupta S., Repessé Y., Bayry J., Navarrete A., Wootla B., Delignat S., et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 109 (2007) 610-612
11. +T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 101 (2003) 1351-1358